$FULC (Fulcrum Therapeutics, Inc.) — investor discussion on X

Most active credible voices on $FULC

@ceostockwatcher (CEO Watcher) — 3 mentions · 16.1K followers
@zohmbastic (zohm) — 2 mentions · 11.4K followers
@mike10947310 (Mike) — 1 mentions · 17.0K followers

Recent headlines featuring $FULC

2026-08-17: Fulcrum and Slate strike all-stock merger at $2.35bn after pociredir exit

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $FULC are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$FULC (Fulcrum Therapeutics, Inc.) — investor discussion on X

Most active credible voices on $FULC

@ceostockwatcher (CEO Watcher) — 3 mentions · 16.1K followers
@zohmbastic (zohm) — 2 mentions · 11.4K followers
@mike10947310 (Mike) — 1 mentions · 17.0K followers

Recent headlines featuring $FULC

2026-08-17: Fulcrum and Slate strike all-stock merger at $2.35bn after pociredir exit

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $FULC are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$FULCFulcrum Therapeutics, Inc. · Biotechnology · $280.8M

$3.68

pre+0.0%

Event thread

Key events, in time order

4 items

2026-08-17 → 08-19Capital
Fulcrum Merges with Slate in All-Stock Deal with $245M Financing
Over-subscribed private financing supports merger; expected close in Q4 with rename to Slate Medicines
D1 +2.7% · +5d +0.0%
2 waves of this story
- 2026-08-17 Combined company to operate as Slate Medicines, focusing on next-gen migraine therapies; deal expected to close in Q4
- 2026-08-19 Over-subscribed private financing supports merger; expected close in Q4 with rename to Slate Medicines
2026-08-178-K filing
8-K: Item 1.01, Item 3.02, Item 5.01, Item 5.02
D1 +2.7% · +5d +0.0%

2 earlier events

2026-08-04Earnings
Earnings report
D1 +2.4% · +5d -2.9%
2026-07-30Earnings
Earnings report
D1 +2.8% · +5d +1.3%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

4 items

2026-08-17 → 08-19Capital
Fulcrum Merges with Slate in All-Stock Deal with $245M Financing
Over-subscribed private financing supports merger; expected close in Q4 with rename to Slate Medicines
D1 +2.7% · +5d +0.0%
2 waves of this story
- 2026-08-17 Combined company to operate as Slate Medicines, focusing on next-gen migraine therapies; deal expected to close in Q4
- 2026-08-19 Over-subscribed private financing supports merger; expected close in Q4 with rename to Slate Medicines
2026-08-178-K filing
8-K: Item 1.01, Item 3.02, Item 5.01, Item 5.02
D1 +2.7% · +5d +0.0%
2026-08-04Earnings
Earnings report
D1 +2.4% · +5d -2.9%
2026-07-30Earnings
Earnings report
D1 +2.8% · +5d +1.3%

$FULC (Fulcrum Therapeutics, Inc.) — investor discussion on X

Most active credible voices on $FULC

Recent headlines featuring $FULC

$FULC (Fulcrum Therapeutics, Inc.) — investor discussion on X

Most active credible voices on $FULC

Recent headlines featuring $FULC

Fulcrum Merges with Slate in All-Stock Deal with $245M Financing

8-K: Item 1.01, Item 3.02, Item 5.01, Item 5.02

Earnings report

Earnings report

Bull vs bear

Discussion

Fulcrum Merges with Slate in All-Stock Deal with $245M Financing

8-K: Item 1.01, Item 3.02, Item 5.01, Item 5.02

Earnings report

Earnings report